Alkaloids as drug leads in Alzheimer's treatment: Mechanistic and therapeutic insights
Issued Date
2024-07-01
Resource Type
ISSN
00068993
eISSN
18726240
Scopus ID
2-s2.0-85190521980
Pubmed ID
38582413
Journal Title
Brain Research
Volume
1834
Rights Holder(s)
SCOPUS
Bibliographic Citation
Brain Research Vol.1834 (2024)
Suggested Citation
Rezaul Islam M., Akash S., Murshedul Islam M., Sarkar N., Kumer A., Chakraborty S., Dhama K., Ahmed Al-Shaeri M., Anwar Y., Wilairatana P., Rauf A., Halawani I.F., Alzahrani F.M., Khan H. Alkaloids as drug leads in Alzheimer's treatment: Mechanistic and therapeutic insights. Brain Research Vol.1834 (2024). doi:10.1016/j.brainres.2024.148886 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/98078
Title
Alkaloids as drug leads in Alzheimer's treatment: Mechanistic and therapeutic insights
Author's Affiliation
Faculty of Tropical Medicine, Mahidol University
University of Swabi
International University of Business Agriculture and Technology
Saveetha Medical College and Hospital
Abdul Wali Khan University Mardan
Taif University
Daffodil International University
Indian Veterinary Research Institute
King Abdulaziz University
IMD Agartala
University of Swabi
International University of Business Agriculture and Technology
Saveetha Medical College and Hospital
Abdul Wali Khan University Mardan
Taif University
Daffodil International University
Indian Veterinary Research Institute
King Abdulaziz University
IMD Agartala
Corresponding Author(s)
Other Contributor(s)
Abstract
Alzheimer's disease (AD) has few effective treatment options and continues to be a major global health concern. AD is a neurodegenerative disease that typically affects elderly people. Alkaloids have potential sources for novel drug discovery due to their diverse chemical structures and pharmacological activities. Alkaloids, natural products with heterocyclic nitrogen-containing structures, are considered potential treatments for AD. This review explores the neuroprotective properties of alkaloids in AD, focusing on their ability to regulate pathways such as amyloid-beta aggregation, oxidative stress, synaptic dysfunction, tau hyperphosphorylation, and neuroinflammation. The FDA has approved alkaloids such as acetylcholinesterase inhibitors like galantamine and rivastigmine. This article explores AD's origins, current market medications, and clinical applications of alkaloids in AD therapy. This review explores the development of alkaloid-based drugs for AD, focusing on pharmacokinetics, blood–brain barrier penetration, and potential adverse effects. Future research should focus on the clinical evaluation of promising alkaloids, developing recently discovered alkaloids, and the ongoing search for novel alkaloids for medical treatment. A pharmaceutical option containing an alkaloid may potentially slow down the progression of AD while enhancing its symptoms. This review highlights the potential of alkaloids as valuable drug leads in treating AD, providing a comprehensive understanding of their mechanisms of action and therapeutic implications.